O’Connor-Semmes, R. L., Lin, J., Hodge, R. J., Andrews, S., Chism, J., Choudhury, A., & Nunez, D. J. (2014). GSK2374697, a novel albumin-binding domain antibody (AlbudAb), extends systemic exposure of exendin-4: first study in humans--PK/PD and safety. Clin Pharmacol Ther., 96(6), 704–704. https://doi.org/10.1038/clpt.2014.187

O’Connor-Semmes, R. L., J. Lin, R. J. Hodge, S. Andrews, J. Chism, A. Choudhury, and D. J. Nunez. “GSK2374697, a novel albumin-binding domain antibody (AlbudAb), extends systemic exposure of exendin-4: first study in humans--PK/PD and safety.” Clin Pharmacol Ther. 96, no. 6 (2014): 704–704. https://doi.org/10.1038/clpt.2014.187.

O’Connor-Semmes RL, Lin J, Hodge RJ, Andrews S, Chism J, Choudhury A, et al. GSK2374697, a novel albumin-binding domain antibody (AlbudAb), extends systemic exposure of exendin-4: first study in humans--PK/PD and safety. Clin Pharmacol Ther. 2014;96(6):704–704.

O’Connor-Semmes, R. L., et al. “GSK2374697, a novel albumin-binding domain antibody (AlbudAb), extends systemic exposure of exendin-4: first study in humans--PK/PD and safety.” Clin Pharmacol Ther., vol. 96, no. 6, 2014, pp. 704–704. Manual, doi:10.1038/clpt.2014.187.

O’Connor-Semmes RL, Lin J, Hodge RJ, Andrews S, Chism J, Choudhury A, Nunez DJ. GSK2374697, a novel albumin-binding domain antibody (AlbudAb), extends systemic exposure of exendin-4: first study in humans--PK/PD and safety. Clin Pharmacol Ther. 2014;96(6):704–704.